The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Intra-individual dose escalation of abiraterone (ABI) according to its plasma exposure in patients (pts) with progressive metastatic castration-resistant prostate cancer (mRCPC): Results of the OPTIMABI trial.
 
Jerome Alexandre
Honoraria - AstraZeneca; Clovis Oncology; Eisai Europe; GlaxoSmithKline; Janssen Oncology; MSD Oncology; MSD Oncology; Novartis; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Eisaï; GlaxoSmithKline; MSD Oncology
Research Funding - Janssen (Inst); MSD Oncology (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo/Astra Zeneca; Janssen; Novartis
 
Stephane Oudard
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; IPSEN; Janssen; Merck; MSD; Novartis; Pfizer; Roche/Genentech; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; IPSEN; Janssen; Merck; MSD Oncology; MSD Oncology; Novartis; Pfizer; Roche; Roche; Sanofi
Research Funding - Ipsen; Sanofi
Travel, Accommodations, Expenses - Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Merck; MSD Oncology; Novartis; Pfizer; Roche
 
Luca Campedel
No Relationships to Disclose
 
Lisa Golmard
No Relationships to Disclose
 
Sylvain Ladoire
Research Funding - Eisai (Inst); Novartis (Inst)
Expert Testimony - Astellas Pharma; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Ipsen; Janssen Oncology; Lilly; Novartis; Pfizer; Roche; Sanofi; Seagen
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Ipsen; Janssen Oncology; Novartis; Pfizer; Sanofi; Seagen
 
Ahmed Khalil
No Relationships to Disclose
 
Denis Maillet
No Relationships to Disclose
 
Christophe Tournigand
Honoraria - Bayer; Bristol-Myers Squibb; MSD; Roche; Sanofi
Consulting or Advisory Role - Bayer
Research Funding - Roche
Travel, Accommodations, Expenses - Bayer; MSD; Roche
 
Françoise Goirand
No Relationships to Disclose
 
Jerome Guitton
No Relationships to Disclose
 
Charles Dariane
Consulting or Advisory Role - Astellas Pharma; Bayer; Janssen
Research Funding - Ipsen
Travel, Accommodations, Expenses - Astellas Pharma
 
Florence Joly
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; GlaxoSmithKline; Ipsen; Janssen; MSD Oncology; Pfizer; Seagen
Travel, Accommodations, Expenses - AstraZeneca; BMS; GlaxoSmithKline; Ipsen; Janssen
 
Evanguelos Xylinas
No Relationships to Disclose
 
Jean Louis Golmard
No Relationships to Disclose
 
Hendy Abdoul
No Relationships to Disclose
 
Nihel Khoudour
No Relationships to Disclose
 
Alicja Puskiel
No Relationships to Disclose
 
Edith Carton
No Relationships to Disclose
 
Olivier Huillard
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Janssen Oncology; Merck; MSD; MSD; Pfizer; Sanofi
Travel, Accommodations, Expenses - Ipsen
 
Benoit Blanchet
No Relationships to Disclose